Halozyme Therapeutics, Inc. (HALO) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 12.47B USD. 52-week range 61.23 to 116.85 USD. Trailing P/E 32.1. Data as of 2026-10-09.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation ...